Company intelligence / Profile preview

Finox Holding

Burgdorf, Bern, Switzerland

Ownership: Private
Employees: ~100
Development stage: Other

Overview

Finox Biotech is a Swiss biopharmaceutical company that focuses on the development and commercialization of fertility products. The company's flagship product, Bemfola (follitropin alfa), is a recombinant human follicle-stimulating hormone (r-hFSH) used to treat infertility. Bemfola was the first biosimilar r-hFSH to be granted marketing authorization in the European Union and is delivered via a unique, award-winning injection pen. In June 2016, Finox Holding was acquired by the Hungarian pharmaceutical company Gedeon Richter for approximately 194 million CHF. This acquisition allowed Gedeon Richter to significantly expand its women's healthcare portfolio into the fertility market.

Therapeutic areas: Women's Health
Modalities: Recombinant proteinBiologic
Industry: Biotech

Beyond the preview

Go deeper on Finox Holding.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Finox Holding.

Explore the full profile